# Prevent Cardiac Surgery Associated AKI Trial

Study · id `cardio:ct-nct06620523` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06620523](<https://clinicaltrials.gov/study/NCT06620523>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06620523

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 242 participants.

## Technical summary

Registry record NCT06620523. Randomized; triple masking; primary purpose treatment. Start 2024-07-18 (actual); primary completion 2027-06-17 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 242 participants (planned count; ClinicalTrials.gov record NCT06620523, source copy `cardio:ctgov-nct06620523-2026-10-14`, retrieved 2026-10-26)
- Started: 2024-07-18 (actual) (ClinicalTrials.gov record NCT06620523, source copy `cardio:ctgov-nct06620523-2026-10-14`, retrieved 2026-10-26)
- Primary completion: 2027-06-17 (anticipated) (ClinicalTrials.gov record NCT06620523, source copy `cardio:ctgov-nct06620523-2026-10-14`, retrieved 2026-10-26)
- Completion: 2028-06-17 (anticipated) (ClinicalTrials.gov record NCT06620523, source copy `cardio:ctgov-nct06620523-2026-10-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06620523, source copy `cardio:ctgov-nct06620523-2026-10-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06620523-2026-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevent Cardiac Surgery Associated AKI Trial
- Condition: Renal Failure
- Condition: Coronary Artery Disease
- Condition: Surgery
- Condition: Surgery-Complications
- Intervention (Drug): CoQ10 1200 mg orally with Glutathione 1000 mg orally
- Intervention (Drug): Group B: Placebo CoQ10 orally and Placebo Glutathione orally
- Lead sponsor: George Washington University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: George Washington University (`cardio:org-george-washington-university`)

## Provenance

Content hash: f54624f96bcf8922b895509d2a4d18e89028684c493788a10464f9983c4a4a12
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
